Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Investors need to pay close attention to NAGE stock based on the movements in the options market lately.
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 75 | $718.46 | $260.99 | -$457.47 | -63.67% |
| BG Bart Gancher Intech Investment Management LLC | 11,306 | $162,919.46 | $39,062.23 | -$123,857.23 | -76.02% |
| KAC Kimberly A. Clarke Stoneridge Investment Partners LLC | 50,641 | $322,000 | $174,964.65 | -$147,035.35 | -45.66% |
Joseph Castro Nuveen LLC | 123,270 | $1.78M | $432,677.7 | -$1.34M | -75.64% |
Jennifer Grunberg Allspring Global Investments Holdings LLC | 18,855 | $240,402.65 | $66,275.32 | -$174,127.33 | -72.43% |